Chemomab Therapeutics Ltd ADR (CMMB) Stock Price, Quote & News

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therape...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 77 331 0156

Website: www.chemomab.com

Address:

Building 7, Kiryat Atidim, Tel Aviv, Israel

DLTT4489 Aug. 24 at 4:17 PM

$CMMB will close $0.40-50 tomorrow

0 · Reply

JoeShmoDoe Aug. 23 at 11:16 AM

$CMMB

0 · Reply

Rolex53 Aug. 22 at 9:21 PM

$CMMB Does some know the ratio of RS. Is it 1:4 ?

1 · Reply

DLTT4489 Aug. 22 at 9:18 PM

$CMMB drop is coming after hours

0 · Reply

DLTT4489 Aug. 22 at 9:18 PM

$CMMB monday will close 0.65, tuesday $2 after split. Then under $ in 2 month and another split before year ends.

0 · Reply

DLTT4489 Aug. 22 at 9:11 PM

$CMMB Next Tuesday 🤣🤣🤣

0 · Reply

TwongStocks Aug. 22 at 7:48 PM

$CMMB NASDAQ Equity Corporate Actions Alert # 2025 - 461 Information Regarding the Reverse Stock Split, Ratio Change, and CUSIP Number Change for Chemomab Therapeutics Ltd (CMMB) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-461 Chemomab Therapeutics Ltd (CMMB) will effect a one-for-four (1-4) reverse split of its American Depositary Shares and ratio change from one (1) American Depositary Share representing twenty (20) Ordinary Shares (1:20) to one (1) American Depositary Share representing eighty (80) Ordinary Shares (1:80). The reverse stock split and ratio change from will become effective on Tuesday, August 26, 2025. In conjunction with the reverse split, the CUSIP number will change to 16385C203.

0 · Reply

MUBSN Aug. 22 at 6:08 PM

$CMMB something big coming

1 · Reply

shreyvakil Aug. 22 at 5:35 PM

$CMMB news leak or shorts covering? 😉

1 · Reply

DLTT4489 Aug. 22 at 12:02 PM

$CMMB All pumpers left you behind with biiiig loss, keep blocking 🚫 the truth🤣🤣🤣 I did whatever i could to warn you to stay away from this scam company but you didn't listen. Now siiiiiit back and watch the show and enjoy the diiiiip.

0 · Reply

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:00 AM EDT - 11 days ago

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 30, 2025, 8:00 AM EDT - 2 months ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

Jun 11, 2025, 8:00 AM EDT - 2 months ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

Jun 3, 2025, 8:00 AM EDT - 2 months ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

May 15, 2025, 8:00 AM EDT - 3 months ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 8:00 AM EDT - 4 months ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Apr 21, 2025, 8:00 AM EDT - 4 months ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Apr 15, 2025, 8:00 AM EDT - 4 months ago

Chemomab Announces New Medical and Clinical Appointments

Mar 27, 2025, 3:18 PM EDT - 5 months ago

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Mar 27, 2025, 8:30 AM EDT - 5 months ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 6, 2025, 8:00 AM EST - 6 months ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 3, 2025, 8:00 AM EST - 6 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Feb 19, 2025, 7:00 AM EST - 6 months ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Dec 3, 2024, 7:00 AM EST - 9 months ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 19, 2024, 7:00 AM EST - 9 months ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Jul 30, 2024, 9:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 25, 2024, 7:38 AM EDT - 1 year ago

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

May 17, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 9, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Mar 25, 2024, 7:06 AM EDT - 1 year ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 7, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Feb 20, 2024, 7:00 AM EST - 1 year ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 5, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Jan 30, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 3, 2024, 7:00 AM EST - 1 year ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Nov 16, 2023, 7:00 AM EST - 1 year ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 15, 2023, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 13, 2023, 8:00 AM EST - 1 year ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 9, 2023, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 4:15 PM EST - 1 year ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Oct 30, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

Oct 26, 2023, 7:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

Jun 28, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

DLTT4489 Aug. 24 at 4:17 PM

$CMMB will close $0.40-50 tomorrow

0 · Reply

JoeShmoDoe Aug. 23 at 11:16 AM

$CMMB

0 · Reply

Rolex53 Aug. 22 at 9:21 PM

$CMMB Does some know the ratio of RS. Is it 1:4 ?

1 · Reply

DLTT4489 Aug. 22 at 9:18 PM

$CMMB drop is coming after hours

0 · Reply

DLTT4489 Aug. 22 at 9:18 PM

$CMMB monday will close 0.65, tuesday $2 after split. Then under $ in 2 month and another split before year ends.

0 · Reply

DLTT4489 Aug. 22 at 9:11 PM

$CMMB Next Tuesday 🤣🤣🤣

0 · Reply

TwongStocks Aug. 22 at 7:48 PM

0 · Reply

MUBSN Aug. 22 at 6:08 PM

$CMMB something big coming

1 · Reply

shreyvakil Aug. 22 at 5:35 PM

$CMMB news leak or shorts covering? 😉

1 · Reply

DLTT4489 Aug. 22 at 12:02 PM

0 · Reply

Newmoves Aug. 21 at 9:18 PM

$CMMB pure crooks at this company doing a reverse split! This is disgusting when they don’t have to do one fleecing investors of more money!

0 · Reply

DLTT4489 Aug. 21 at 7:18 PM

$CMMB buy and buy, then bye and bye

0 · Reply

DLTT4489 Aug. 21 at 7:18 PM

$CMMB @shreyvakil and other paid pumpers trying to convince you to buy the diiiiiiip 🤣🤣🤣🤣🤣

0 · Reply

DLTT4489 Aug. 21 at 7:17 PM

$CMMB oh boy, pre-earthquake time. Get ready. Just get ready Real earthquake and tsunami will come next week

0 · Reply

DLTT4489 Aug. 21 at 2:28 PM

$CMMB if you can trust a company that doesn't ask investors for major changes like RS, go ahead and invest in, and you'll see what happens.

0 · Reply

DLTT4489 Aug. 21 at 1:17 PM

$CMMB place your order @ 0.10, will filled quickly

0 · Reply

DLTT4489 Aug. 21 at 1:15 PM

$CMMB Exactly. those are the same people/pumpers who would've thought this garbage will be around $80,$100,.... in 2022,2023, 2024, 2025, ....... This $H!!!!t will sink quickly to the hell. I've been saying this for months and came through. Look at $AIM $JAGX...... Ask them if you think RS is good😅😅

2 · Reply

JoeShmoDoe Aug. 21 at 11:44 AM

$CMMB eh it’s at 0!

0 · Reply

Tabi04 Aug. 21 at 12:19 AM

$CMMB reverse split is never a good news for investors. Whoever is thinking that split will do nothing to the stock then check your average price after the split 😂

0 · Reply

DLTT4489 Aug. 20 at 8:21 PM

$CMMB Be prepared for next Tuesday, ill see you all next week

0 · Reply

BUKUDATBULL Aug. 20 at 2:21 PM

OHHH 😮 And $CMMB looking a lil cute right now to (;

0 · Reply

JoeShmoDoe Aug. 20 at 3:11 AM

$CMMB who’s buying this pos?

0 · Reply

Market Cap	16.78M
Revenue (ttm)	0.00
Net Income (ttm)	-13.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	311,500
Avg Vol	150,242
Day's Range	N/A - N/A
Shares Out	18.86M
Stochastic %K	7%
Beta	0.52
Analysts	Strong Sell
Price Target	$8.67